A four-way crossover study to examine the effects of lapatinib on the pharmacokinetics of orally and intravenously administered midazolam in cancer patients
Latest Information Update: 06 Sep 2023
At a glance
- Drugs Lapatinib (Primary) ; Midazolam; Midazolam
- Indications Breast cancer; Cancer; Colorectal cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors GSK
- 01 Dec 2017 Results assessing effect of Lapatinib on CYP3A metabolism of Midazolam published in the Cancer Chemotherapy and Pharmacology
- 22 Dec 2005 New trial record.